Trinity Biotech PLC (TRIB) income statement
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 30, 2026Score 1/30
$5.83−0.18 (-3.08%)
Close on Nov 18, 2026Market cap $108.99MP/E –Yield –
Trinity Biotech PLC income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- 38.6%
- Operating margin
- -36.1%
- Net margin
- -85.4%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 0.25
- Debt to equity
- –
- Debt to assets
- 0.2%
- Cash to current liabilities
- 3.6%
Valuation
- P/E ratio
- –
- Price to sales
- 2.49
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?